Miro clears TGA audit ahead of Crohn’s disease trial
Full story
Miro Sciences passed a manufacturing audit conducted by the TGA. The regulator inspected a partner's facility. This step is necessary before starting a Phase 2 study for a cell therapy called StemSmart designed for Crohn's disease.
Miro Sciences has cleared a TGA manufacturing hurdle for its Crohn’s trial, with the regulator inspecting its partner’s facility ahead of a planned Phase 2 study for its StemSmart cell therapy.